CytomX Therapeutics, Inc. (CTMX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 3 d154321dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 CYTOMX THERAPEUTICS, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN Amended and Restated: March 19, 2025 Approved by Stockholders: June 11, 2025 (as Amended by the Board: March 18, 2026) I. INTRODUCTION 1.1 Purposes .
How this was made
The 30-second read
Why it matters
This is a governance/compensation disclosure. Traders may monitor for follow-on details (who changed roles, any new employment agreements, and any updated share pool or award mechanics) that could affect dilution and retention narratives.
Market read
Primary SEC filing, but the provided text is mostly plan definitions; without quantified changes or named executive terms, near-term trading impact is likely modest.
What to watch
The excerpt does not show the specific director/officer names, effective dates, or any quantified share pool/award changes; those details could materially affect dilution and retention expectations.
Background
The company’s 8-K references Item 5.02 (director/officer departure/election/appointment and compensatory arrangements) and Item 5.07 (matters submitted to a vote of security holders), with an attached amended and restated equity incentive plan.
Ticker impact
CytomX filed an 8-K for director/officer changes and amended its 2015 equity incentive plan, effective after stockholder approval.
Likely limited immediate price impact; any effect would be via longer-term dilution/retention expectations rather than a discrete earnings or deal catalyst.
The filing is a primary SEC disclosure (8-K) but the provided excerpt is largely plan boilerplate and does not include specific new financial terms, grants, or a named executive departure/appointment with material details.
Market effects
Minor read-through for biotech/biopharma governance norms; equity-plan amendments are common and usually not sector-moving absent quantified dilution or major leadership turnover.
None indicated.
None indicated.
Counterpoint
If the plan amendment enables materially larger equity grants or changes performance/vesting mechanics, the market may re-rate dilution risk even without an explicit earnings catalyst.
Key entities
- issuerCytomX Therapeutics, Inc.
Subject of the SEC 8-K; filed director/officer change disclosures and an amended and restated 2015 equity incentive plan.
